Highly active anti-retroviral therapy (HAART) and prophylactic therapy for opportunistic infection have significantly improved the survival and quality of life for patients infected with the Human Immunodeficiency Virus (HIV) lymphocyte count <100 p/1 and extranodal disease, particularly central nervous system involvement. The overall survival is usually less than 1 year.6 Several chemotherapy regimens have been investigated and an initial randomised trial comparing a low dose and standard dose chemotherapy regime (mBACOD) with granulocyte -macrophage colony stimulating factor (GIVI-CSF) support showed no difference in response or survival in the two groups however there was an increase in the incidence of neutropenic sepsis in the full dose arm.7 Recently developed protocols have resulted in improved response and survival rates, particularly in good risk patients. There is also the suggestion of improved survival since the introduction of HAART in 1996 with further studies required for confirmation.8' 9 Acute B cell lymphoblastic leukaemia (B ALL) is characteristically associated with central nervous system involvement and a poor prognosis. The cytogenetic abnormality t(8: 14) is present in the majority ofcases this resulting in dysregulation of the c-myc proto-oncogene which is implicated in pathogenesis. Morphology is characteristic with blast cells exhibiting strongly basophilic cytoplasm and vacuolation (Figure) . Recent 
